Ceftolozane/Tazobactam 1000/500 mg + Ceftolozane/Tazobactam 30/15 mg/kg + Ceftolozane/Tazobactam 20/10 mg/kg + Ceftolozane/Tazobactam 18/9 mg/kg + Ceftolozane/Tazobactam 12/6 mg/kg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Proven or Suspected Gram-negative Bacterial Infection
Conditions
Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis
Trial Timeline
Sep 17, 2014 → Jun 15, 2017
NCT ID
NCT02266706About Ceftolozane/Tazobactam 1000/500 mg + Ceftolozane/Tazobactam 30/15 mg/kg + Ceftolozane/Tazobactam 20/10 mg/kg + Ceftolozane/Tazobactam 18/9 mg/kg + Ceftolozane/Tazobactam 12/6 mg/kg
Ceftolozane/Tazobactam 1000/500 mg + Ceftolozane/Tazobactam 30/15 mg/kg + Ceftolozane/Tazobactam 20/10 mg/kg + Ceftolozane/Tazobactam 18/9 mg/kg + Ceftolozane/Tazobactam 12/6 mg/kg is a phase 1 stage product being developed by Merck for Proven or Suspected Gram-negative Bacterial Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT02266706. Target conditions include Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02266706 | Phase 1 | Completed |
Competing Products
3 competing products in Proven or Suspected Gram-negative Bacterial Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| esomeprazole magnesium | AstraZeneca | Phase 1 | 33 |
| ASA404 | Novartis | Phase 1 | 33 |
| R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7 | PDS Biotechnology | Phase 1 | 25 |